A jury in Boston has recommended that Neovasc Inc. pay Edwards Lifesciences Corp. subsidiary CardiAQ Valve Technologies Inc. $70m in damages to resolve a two-year old lawsuit, Edwards announced May 19.
The jury in the United States District Court for the District Of Massachusetts said Neovasc breached a nondisclosure agreement while it was a supplier for CardiAQ, misappropriated CardiAQ’s trade secrets...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?